Dr. Elizabeth E. Gerber presented research on rare glutamate receptor variants and their role in schizophrenia during a Grand Rounds lecture [1].

The findings challenge traditional medical perspectives by shifting the focus away from dopamine-centric models. Understanding these specific genetic variants could lead to more precise diagnostic tools, and targeted treatments for patients who do not respond to standard medications.

The presentation, titled "Beyond Dopamine: What Rare Glutamate Receptor Variants Reveal About Schizophrenia," took place on March 30, 2026 [1]. The event was hosted by the Johns Hopkins Psychiatry and Behavioral Sciences department within Johns Hopkins Medicine [1].

Gerber said rare variants in glutamate receptors provide new insights into the biological mechanisms of the disorder. While dopamine has long been the primary focus of schizophrenia research, the lecture highlighted the significance of glutamate—the brain's primary excitatory neurotransmitter—in shaping the pathology of the condition [1].

This research focuses on the intersection of genetics and psychiatry. By identifying rare variants, researchers can better understand how specific protein dysfunctions contribute to the cognitive, and behavioral symptoms associated with schizophrenia [1].

The lecture served as a forum for medical professionals to examine the evolving landscape of neuropsychiatry. The discussion emphasized the need for a broader biochemical understanding of the brain to improve patient outcomes [1].

“Beyond Dopamine: What Rare Glutamate Receptor Variants Reveal About Schizophrenia”

This shift toward glutamate receptor research represents a pivot in psychiatric science. For decades, the 'dopamine hypothesis' dominated the treatment of schizophrenia, primarily through the use of antipsychotics that block dopamine receptors. By identifying rare genetic variants in the glutamate system, researchers may be able to develop a new class of therapeutics that address the root cause of the disorder rather than just managing symptoms.